BridgeMD
LIDOCRIT : Effect of continuous intravenous LIDOCaine on discomfort in postoperative CRITical care inpatients
EU CTIS ID: 2024-517749-15-00
What this study is testing
To determine whether continuous intravenous administration of Lidocaine during the first 48 hours post-operatively improves patients' perceived comfort during their stay in the intensive care unit and continuous monitoring unit (critical care). Within 24 hours before discharge from critical care or, failing that, within 24 hours before the 15th day of hospitalization in critical care.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Major patient
- Patient admitted immediately post-operatively in critical care (scheduled or emergency admission, e.g. post-operative exploratory laparotomy, cardiac surgery, heavy orthopaedic surgery such as polytrauma patients, vascular surgery at risk of complications such as open aortic surgery)
- Anticipated length of stay in critical care ≥ 48h
- Membership of a social security scheme
- Informed consent must be obtained and signed by the patient or by a close relative or legal representative or, failing that, the emergency procedure must be followed
You likely can't join if
- Weight over 100 kg
- Stage IV/V chronic renal failure, not on dialysis
- Severe hepatocellular insufficiency at inclusion (Child-Pugh C)
- Bradycardia < 50 bpm on antiarrhythmic drugs
- Clinical convulsive seizure at inclusion
- Predictable inability to answer the questionnaire (cognitive impairment, non-Francophone)
See the full eligibility criteria
- Major patient
- Patient admitted immediately post-operatively in critical care (scheduled or emergency admission, e.g. post-operative exploratory laparotomy, cardiac surgery, heavy orthopaedic surgery such as polytrauma patients, vascular surgery at risk of complications such as open aortic surgery)
- Anticipated length of stay in critical care ≥ 48h
- Membership of a social security scheme
- Informed consent must be obtained and signed by the patient or by a close relative or legal representative or, failing that, the emergency procedure must be followed
- Weight over 100 kg
- Stage IV/V chronic renal failure, not on dialysis
- Severe hepatocellular insufficiency at inclusion (Child-Pugh C)
- Bradycardia < 50 bpm on antiarrhythmic drugs
- Clinical convulsive seizure at inclusion
- Predictable inability to answer the questionnaire (cognitive impairment, non-Francophone)
- Known participation in another interventional research study (RIPH1 or RIPH2)
- Known situation of deprivation of liberty or legal protection (safeguard of justice, guardianship or curatorship)
- Hypersensitivity to one of the active substances used for anaesthesia or to one of the excipients
- Acute porphyria on anamnesis
- Pregnant or breast-feeding women
- Patient who has received or will receive peri-medullary analgesia intra-operatively or post-operatively
- Patient who has received or will receive loco-regional analgesia intra-operatively or post-operatively
- Severe head injury, open cephalic neurosurgery, interventional neuroradiology
- Recovered cardiorespiratory arrest
- Noradrenaline doses > 0.5 μg/kg/min
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.